Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia"
DOI: 10.1038/leu.2017.46
Abstract: Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). Here we… read more here.
Keywords: idh1; myeloid; bay1436032; leukemia ... See more keywords
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2022.2138331
Abstract: ABSTRACT Introduction The combination of gemcitabine and cisplatin remains the standard-of-care first-line therapeutic option in patients with the unresectable disease based on the encouraging phase II and phase III trials (ABC-02). Recently, the combination of… read more here.
Keywords: idh1 mutant; cholangiocarcinoma; combination; ivosidenib ... See more keywords
PRMT1 driven PTX3 regulates ferritinophagy in glioma.
Sign Up to like & getrecommendations! Published in 2023 at "Autophagy"
DOI: 10.1080/15548627.2023.2165757
Abstract: Mutations in the Krebs cycle enzyme IDH1 (isocitrate dehydrogenase (NADP(+)) 1) are associated with better prognosis in gliomas. Though IDH1 mutant (IDH1R132H) tumors are characterized by their antiproliferative signatures maintained through hypermethylation of DNA and… read more here.
Keywords: idh1 mutant; idh1; ptx3; prmt1 ... See more keywords
EXTH-10. COMBINATION OF EPIGENETIC ENZYME INHIBITORS, GSK-J4 AND BELINOSTAT, REVEALS HIGH EFFICACY IN IDH1 MUTANT GLIOMAS
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-oncology"
DOI: 10.1093/neuonc/noaa215.364
Abstract: Mutations in IDH1 and IDH2 genes are common in low grade gliomas and secondary GBM and are known to cause a distinct epigenetic landscape in these tumors. To interrogate the epigenetic vulnerabilities of IDH-mutant gliomas,… read more here.
Keywords: combination; gsk belinostat; idh1 mutant; gliomas ... See more keywords
Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in paediatrics.
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-oncology"
DOI: 10.1093/neuonc/noac132
Abstract: BACKGROUND The incidence and biology of IDH1/2 mutations in pediatric gliomas are unclear. Notably, current treatment approaches by pediatric and adult providers vary significantly. We describe the frequency and clinical outcomes of IDH1/2-mutant gliomas in… read more here.
Keywords: mutant glioma; idh1 mutant; multi institutional; frequency ... See more keywords
The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noac155
Abstract: Abstract Background Approximately 70% of lower-grade gliomas harbor isocitrate dehydrogenase 1 (IDH1) mutations, resulting in the accumulation of oncometabolite D-2-hydroxyglutarate (D-2-HG); this leads to epigenetic dysregulation, oncogenesis, and subsequent clonal expansion. DS-1001 is an oral… read more here.
Keywords: idh1 mutant; idh1; recurrent progressive; brain ... See more keywords
PO-253 Characteristics of cellular respiration, glycolytic activity and related metabolic features in wild type and IDH1 mutant glioma cells
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.286
Abstract: Introduction IDH mutations are expressed in 80% of low grade gliomas and secondary glioblastomas with a favourable prognosis comparing to non IDH mutant gliomas [According to WHO (2016)] classification, IDH1 mutation is an important marker… read more here.
Keywords: idh1 mutant; respiration; glycolytic activity; idh1 ... See more keywords
Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.2577
Abstract: 2577Background: Mutant isocitrate dehydrogenase 1 (mIDH1) produces the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (IVO; AG-120) is a targeted mIDH1 inhibitor under evaluation in an ongo... read more here.
Keywords: pharmacodynamics ivosidenib; ivosidenib patients; patients idh1; mutant advanced ... See more keywords
Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.2581
Abstract: 2581Background: Mutant isocitrate dehydrogenase 1 (mIDH1) produces the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (IVO) is a selective mIDH1 inhibitor under evaluation in patients with ... read more here.
Keywords: clinical pharmacokinetics; pharmacodynamics ivosidenib; patients idh1; idh1 mutant ... See more keywords
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.7500
Abstract: 7500Background: Mutations in the isocitrate dehydrogenase-1 gene (IDH1) result in myeloid differentiation arrest and accumulation of the oncometabolite 2-hydroxyglutarate (2-HG), promoting leukemog... read more here.
Keywords: inhibitor; study idh1; idh1; mutant inhibitor ... See more keywords
Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Nutrition"
DOI: 10.3389/fnut.2021.682243
Abstract: Background: Successful treatment of glioblastoma (GBM) remains futile despite decades of intense research. GBM is similar to most other malignant cancers in requiring glucose and glutamine for growth, regardless of histological or genetic heterogeneity. Ketogenic… read more here.
Keywords: gbm; long term; management; report ... See more keywords